TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04455542

Intervention type: OTHER
Intervention: LMND-ALS
Description: in line with LMND -ALS inclusion criteria, and CMAP amplitude of peripheral motor nerves (CMAP amplitude of the 10 peripheral motor nerves with the most obvious CMAP amplitude decline was selected as the CMAP amplitude for grouping of the patients) was less than the median of CMAP amplitude of LMND -ALS group.

Intervention type: OTHER
Intervention: UMND-ALS
Description: The main clinical manifestations were limb stiffness and spasm, obvious pyramidal tract signs, relatively mild muscle atrophy and fasciculation, and no significant decrease in amplitude of electromyography CMAP.

Intervention type: OTHER
Intervention: FAS and FLS
Description: The clinical symptoms were confined to upper limbs (FAS) or lower limbs (FLS) for more than 12 months, and the main manifestations were lower motor neuron involvement signs such as muscle weakness and atrophy.
Study: NCT00817739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin
Description: Leuprorelin injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Description: Leuprorelin injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide
Description: Flutamide tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Flutamide tablets
Study: NCT00179478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon beta 1a 30 ug IM once weekly
Description: Immediate treatment group refers to those patients who were randomized to the interferon beta 1a 30 ug IM once weekly treatment arm of the original, controlled phase III CHAMPS study; Delayed treatment group refers to those patients who were randomized to the placebo group during the original controlled, phase III CHAMPS study and did not start treatment, if at all, until they completed the CHAMPS study protocol at a later date.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon beta 1a 30 ug IM once weekly
Description: Immediate treatment group refers to those patients who were randomized to the interferon beta 1a 30 ug IM once weekly treatment arm of the original, controlled phase III CHAMPS study; Delayed treatment group refers to those patients who were randomized to the placebo group during the original controlled, phase III CHAMPS study and did not start treatment, if at all, until they completed the CHAMPS study protocol at a later date.
Study: NCT04471298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qishenyiqi dripping pills, 6 bags
Description: 28 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qishenyiqi dripping pills, 9 bags
Description: 28 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qishenyiqi dripping pills, 12 bags
Description: 28 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qishenyiqi dripping pills placebo, 6 bags
Description: 28 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qishenyiqi dripping pills placebo, 9 bags
Description: 28 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qishenyiqi dripping pills placebo, 12 bags
Description: 28 consecutive days
Study: NCT04550455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine Tablets
Description: Cladribine tablets will be administered according the current package insert guidelines
Study: NCT04750772

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG and 68Ga-DOTA-FAPI04 PET/CT
Description: Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI04, and undergo PET/CT imaging within the specified time

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG and 18F-DOTA-FAPI04 PET/CT
Description: Each subject receive a single intravenous injection of 18F-FDG and 18F-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
Study: NCT04794439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrices
Description: Dentifrice on plaque

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrices
Description: Dentifrice on plaque

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrices
Description: Dentifrice on plaque

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrices
Description: Dentifrice on plaque
Study: NCT05226728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Eligible patients received pembrolizumab 200mg every 3 weeks with or without chemotherapy for four cycles, then for patients without progressive disease, pembrolizumab was administrated in new dose-intervals according to steady state plasma-concentration (Css) of pembrolizumab until disease progression
Study: NCT05980078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive consent
Description: They were randomized to complete an interactive consent.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard consent
Description: They were randomized to complete a standard written consent.
Study: NCT02607956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTG
Description: 50 mg tablets administered orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F/TAF
Description: 200/25 mg tablets administered orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 milligrams (mg) FDC tablets administered orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 milligrams (mg) FDC tablets administered orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 milligrams (mg) FDC tablets administered orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG Placebo
Description: Tablets administered orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF Placebo
Description: Tablets administered orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B/F/TAF Placebo
Description: Tablets administered orally, once daily
Study: NCT02354144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carrageenan-based gel
Description: Carrageenan is a non-toxic gelling agent safe in animals and humans as a potent HPV inhibitor. An anionic polymer derived from red algae, carrageenan has a long history of human use as a stabilizer and emulsifier in many industries. All three major classes of carrageenan act as extremely potent HPV inhibitors and block HPV infection by binding to the viral capsid, thus preventing attachment to the appropriate cell-surface heparan sulfate proteoglycans (HSPG) receptors.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control gel
Description: A gel not containing carrageenan
Study: NCT03542604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: CBT-I involves identifying and replacing thoughts and behaviors that cause or worsen sleep problems with habits that promote sound sleep. There will be 6 intervention sessions over an 8-week period. The first two sessions are consecutive weekly in-person sessions followed by a rest week. The third session is conducted remotely by phone, followed by another rest week. The three remaining sessions are weekly and conducted remotely.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Education
Description: EDU involves learning behavioral treatment information about sleep that is widely available to patients and practitioners. The program will parallel the CBT-I intervention in schedule, number, and length of sessions.
Study: NCT00001806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Education and Counseling
Description: Group Education and Counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genetic Education and Counseling
Description: Individual Education and Counlseing
Study: NCT03987815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab
Study: NCT03820388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 2mg/kg
Description: 2 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg/kg
Description: 0.3 mg/kg
Study: NCT01821040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lodotra®
Description: Lodotra, starting dose of 15mg administered in the evening
Study: NCT03820388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 1 mg/kg
Description: 1 mg/kg Propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate 0.15 mg/kg
Description: 0.15 mg/kg Etomidate
Study: NCT01821040

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone IR (immediate release)
Description: Prednisone IR 15mg daily start dose (immediate release) administered in the morning,
Study: NCT01745835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2L Coolprep®
Description: \* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1L Coolprep® and Bisacodyl
Description: 1. Coolprep® (TaeJoon Pharmaceuticals, Seoul, Korea)~   \* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g~2. Dulcolax-S® (Boehringer Ingelheim ,Seoul, Korea) \* composition /1 tablet : Bisacodyl 5mg, docusate sodium 16.75mg
Study: NCT03710850

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin is a dietary fibre. Will be supplemented in a dose 10g/d for a period of 3 moths.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin is a dietary fibre. Will be supplemented in a dose 10g/d for a period of 3 moths.
Study: NCT00742560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: elotuzumab
Description: Humanized Anti-CS1 Monoclonal IgG1 Antibody (HuLuc63) administered as an intravenous infusion once a week during Cycles 1 and 2, and every other week beginning with Cycle 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: elotuzumab
Description: Humanized Anti-CS1 Monoclonal IgG1 Antibody (HuLuc63) administered as an intravenous infusion once a week during Cycles 1 and 2, and every other week beginning with Cycle 3.
Study: NCT03016260

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Anti-TNF alpha originator

Intervention type: BIOLOGICAL
Intervention: Adalimumab
Description: Anti-TNF alpha originator

Intervention type: BIOLOGICAL
Intervention: Etanercept
Description: Anti-TNF alpha originator

Intervention type: BIOLOGICAL
Intervention: Golimumab
Description: Anti-TNF alpha originator
Study: NCT00742560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: elotuzumab
Description: Humanized Anti-CS1 Monoclonal IgG1 Antibody (HuLuc63) administered as an intravenous infusion once a week during Cycles 1 and 2, and every other week beginning with Cycle 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: elotuzumab
Description: Humanized Anti-CS1 Monoclonal IgG1 Antibody (HuLuc63) administered as an intravenous infusion once a week during Cycles 1 and 2, and every other week beginning with Cycle 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: elotuzumab
Description: Humanized Anti-CS1 Monoclonal IgG1 Antibody (HuLuc63) administered as an intravenous infusion once a week during Cycles 1 and 2, and every other week beginning with Cycle 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide 25 mg administered orally once daily on Days 1 to 21 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide 25 mg administered orally once daily on Days 1 to 21 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide 25 mg administered orally once daily on Days 1 to 21 of each 28-day cycle
Study: NCT03016260

Intervention type: BIOLOGICAL
Intervention: Certolizumab Pegol
Description: Anti-TNF alpha originator

Intervention type: BIOLOGICAL
Intervention: Infliximab biosimilar
Description: Anti-TNF alpha Infliximab biosimilars
Study: NCT04584593

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Sample
Description: Men will give semen, saliva, nasopharyngeal, urine and blood specimens
Study: NCT00582777

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: USUAL - take your BP Meds as you usually do
Description: The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HS DOSING
Description: Take your usual BP meds at bed time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADD On Dosing
Description: Take your usual BP meds but add one more med at bed time.
Study: NCT02138968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Description: Multidimensional intervention based on: good control of baseline diseases, review of medication adequacy, exercise program, nutritional assessment and control, social assessment and control.
Study: NCT00551603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: switch (epoetinum beta, darbepoetinum)
Description: switching from epoetinum beta once weekly to once-fortnightly darbepoetinum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuation (darbepoetinum)
Description: continuation of the previous darbepoetinum administration schedule
Study: NCT02860715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This is the placebo of GX-I7 described above.
Study: NCT03016260

Intervention type: BIOLOGICAL
Intervention: Etanercept biosimilar
Description: Anti-TNF alpha Etanercept biosimilar
Study: NCT02860715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This is the placebo of GX-I7 described above.
Study: NCT03016260

Intervention type: BIOLOGICAL
Intervention: Infliximab biosimilar
Description: Anti-TNF alpha Infliximab biosimilar
Study: NCT03279731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
Description: subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). It is designed to be identical to the pen used for liraglutide (Saxenda). Placebo product inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection
Study: NCT00742560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide 25 mg administered orally once daily on Days 1 to 21 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide 25 mg administered orally once daily on Days 1 to 21 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone oral
Description: Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone oral
Description: Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone oral
Description: Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone oral
Description: Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone oral
Description: Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone injection
Description: Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone injection
Description: Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone injection
Description: Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
Study: NCT00742560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone injection
Description: Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone injection
Description: Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
Study: NCT04153500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anatomy class with Pelvic+ methodology
Description: Teaching of female pelvis anatomy using a interactive training model (Pelvic+ methodology)
Study: NCT01455012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine 1 mg/24 h, 2 mg/24 h, and 3 mg/24 h. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
Study: NCT00735878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-751 and Carboplatin
Description: This primary objective of this Phase 1/2 study is to evaluate the DLT and MTD of escalating oral doses of ABT-751 given BID on Day 1 of each cycle for 7 days in combination with carboplatin given on a 21-day schedule. The carboplatin dose is fixed at AUC 6 and will be administered on Day 4 during the first cycle to facilitate the pharmacokinetic analysis. During the subsequent cycles both agents will be administered on Day 1. ABT-751 is administered at the following dose levels using the Simon rapid dose escalation model: 100, mg, 125 mg, 150 mg, 175 mg and 200 mg BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-751 and Carboplatin
Description: This primary objective of this Phase 1/2 study is to evaluate the DLT and MTD of escalating oral doses of ABT-751 given BID on Day 1 of each cycle for 7 days in combination with carboplatin given on a 21-day schedule. The carboplatin dose is fixed at AUC 6 and will be administered on Day 4 during the first cycle to facilitate the pharmacokinetic analysis. During the subsequent cycles both agents will be administered on Day 1. ABT-751 is administered at the following dose levels using the Simon rapid dose escalation model: 100, mg, 125 mg, 150 mg, 175 mg and 200 mg BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-751 and Carboplatin
Description: This primary objective of this Phase 1/2 study is to evaluate the DLT and MTD of escalating oral doses of ABT-751 given BID on Day 1 of each cycle for 7 days in combination with carboplatin given on a 21-day schedule. The carboplatin dose is fixed at AUC 6 and will be administered on Day 4 during the first cycle to facilitate the pharmacokinetic analysis. During the subsequent cycles both agents will be administered on Day 1. ABT-751 is administered at the following dose levels using the Simon rapid dose escalation model: 100, mg, 125 mg, 150 mg, 175 mg and 200 mg BID.
Study: NCT01059370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bowel emptying
Description: Bowel is emptied using Peristeen® irrigation system one day, by digital stimulation another trial day or filling the bladder with saline water on a third trial day. BP is measured by Finometer Pro®, respiration frequency by BIOPACK and skin conductivity measured by Biopack and nor-epinephrine and epinephrine are measured in plasma three times during each examination.
Study: NCT03320564

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: F-18 FDG PET
Description: Repeat scan performed by specially trained staff to reduce risk of repeat infiltration.
Study: NCT03320772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMVP1-ICG
Description: Detection of SLN

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICG
Description: Detection of SLN